Hosoya Y, Arai K, Honda M, Sumi S, Yoshida K
Department of Urology, Dokkyo University School of Medicine, Mibu, Japan.
Eur Urol. 1997;31(2):220-3. doi: 10.1159/000474454.
To evaluate serum levels of the carboxy-terminal propeptide of type I procollagen (PICP) and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) as possible markers of bone metastases in patients with prostate carcinoma (PCA) patients.
Levels of PICP and ICTP were measured by radioimmunoassay of serum from 29 patients with benign prostatic hyperplasia (BPH), 17 patients with PCA without bone metastases and 29 patients with PCA and bone metastases.
Serum levels of PICP in patients with PCA and bone metastases (mean +/- SD 304.3 +/- 365.9 ng/ml) were significantly higher than those in patients with BPH (95.6 +/- 27.1 ng/ml) and in patients with PCA without bone metastases (111.1 +/- 44.6 ng/ml). No significant difference was observed between the BPH and the PCA without bone metastases groups. Serum levels of ICTP were significantly higher in the PCA with (10.4 +/- 10.3 ng/ml) and without bone metastases groups (7.7 +/- 6.0 ng/ml) than in the BPH group (3.7 +/- 2.0 ng/ml). There was no significant difference between the PCA groups with and without bone metastases.
Serum PICP levels correlate well with results of bone scans, while serum ICTP levels increase in patients with PCA regardless of the presence of bone metastases.
评估血清I型前胶原羧基端前肽（PICP）和I型胶原吡啶啉交联羧基末端肽（ICTP）水平，作为前列腺癌（PCA）患者骨转移的可能标志物。
采用放射免疫分析法测定29例良性前列腺增生（BPH）患者、17例无骨转移的PCA患者和29例有骨转移的PCA患者血清中的PICP和ICTP水平。
有骨转移的PCA患者血清PICP水平（均值±标准差304.3±365.9 ng/ml）显著高于BPH患者（95.6±27.1 ng/ml）和无骨转移的PCA患者（111.1±44.6 ng/ml）。BPH组和无骨转移的PCA组之间未观察到显著差异。有骨转移的PCA组（10.4±10.3 ng/ml）和无骨转移的PCA组（7.7±6.0 ng/ml）血清ICTP水平显著高于BPH组（3.7±2.0 ng/ml）。有骨转移和无骨转移的PCA组之间无显著差异。
血清PICP水平与骨扫描结果密切相关，而无论是否存在骨转移，PCA患者血清ICTP水平均会升高。
